Showing 7601-7610 of 9718 results for "".
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- Navigating Antibiotic Use for Acne and Rosacea: Clinician Insights and Considerationshttps://practicaldermatology.com/news/navigating-antibiotic-use-for-acne-and-rosacea-clinician-insights-and-considerations/2462208/Growing apprehensions surrounding antibiotic resistance in acne and rosacea treatments, coupled with their linked
- Researchers ID Genetic Risk Factors for Early-Onset Merkel Cell Carcinomahttps://practicaldermatology.com/news/researchers-id-genetic-risk-factors-in-early-onset-mcc/2462201/New research indicates that germline variants in genes are significantly associated with early-onset Merkel cell carcinoma (MCC). The case-control study included 1,012 individuals (37 of whom had early-onset MCC, 45 with later-onset MCC, and 930 controls) who were prospectively enrolled
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of
- Venous Thromboembolism Risk Lower in AD Patients: Analysishttps://practicaldermatology.com/news/venous-thromboembolism-risk-lower-in-ad-patients-analysis/2462196/A retrospective, observational analysis in the Journal of the American Academy of Dermatology showed that patients with atopic dermatitis (AD) do not have an increased risk for venous thromboembolism (VTE) compared with other immune-mediated inflammatory diseases. The ana
- Analysis: Vegetarian Diet during Pregnancy Lowers Risk of AD in Childrenhttps://practicaldermatology.com/news/association-between-a-maternal-vegetarian-diet-during-pregnancy-and-the-occurrence-of-atopic-dermatitis-in-children/2462188/A new study published in Pediatric Allergy and Immunology suggested that a vegetarian diet during pregnancy was associated with a reduced risk for atopic dermatitis (AD) in children. Researchers
- Can-Fite Receives Positive Response from FDA for Psoriasis Pediatric Planhttps://practicaldermatology.com/news/can-fite-receives-positive-response-from-fda-for-psoriasis-pediatric-plan/2462187/The U.S. Food and Drug Administration (FDA) gave a positive response to a study plan for piclidenoson in children suffering from psoriasis. The plan allows for children to enroll in the phase 3 pivotal clinical study aiming at registering the drug with both the FDA as well as the Europe